Search clinical trials for: Relapse or progression

Total 206964 results

Shanxi Bethune Hospital
Antengene Corporation

Recruiting

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia

China
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
Jagiellonian University

Recruiting

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease (ChIm-NB-PL)

High-Risk Neuroblastoma

Poland
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); Roswell Park Cancer Institute; American Lebanese...

Recruiting

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Glioblastoma Multiforme | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | High-grade Astrocytoma NOS

United States, Canada
Mansoura University

Recruiting

The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence

Death | Wilms Tumor | Relapse

Egypt
Hospices Civils de Lyon

Recruiting

Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

Progressive Idiopathic Pulmonary Fibrosis

France
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

France, Denmark, Netherlands
UNICANCER
Sanofi

Active, not recruiting

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse (PEACE2)

Adenocarcinoma of Prostate | Progression of Prostate Cancer

France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Leukemia

United States
Regeneron Pharmaceuticals

Active, not recruiting

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma (RRMM)

United States
Novartis Pharmaceuticals

Active, not recruiting

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Carcinoma, Renal Cell

Spain, Singapore, Czechia, Italy, Japan, France, United States
Lawson Health Research Institute
The Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health System

Active, not recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage III

Canada
Richard Stone, MD
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Active, not recruiting

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University Hospital, Basel, Switzerland
Swiss Foundation for the Study of Muscular Diseases

Completed

Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course

Giant Cell Arteritis | Large Vessel Giant Cell Arteriitis

Switzerland
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
ARCAGY/ GINECO GROUP
Hoffmann-La Roche

Active, not recruiting

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (ATALANTE)

Ovarian Cancer

Spain, Belgium, France, Germany, Austria, Czechia, Israel
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States, Canada
NCIC Clinical Trials Group

Completed

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Lymphoma

United States, Canada, Australia
University of Virginia
Pfizer; University of Wisconsin, Madison; Vanderbilt University; Virginia Commonwealth...

Active, not recruiting

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001)

B-cell Acute Lymphoblastic Leukemia

United States
NCIC Clinical Trials Group
Cascadian Therapeutics Inc.

Completed

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Glioblastoma

Canada
Therapeutic Advances in Childhood Leukemia Consortium
Pfizer

Completed

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Lymphoblastic Lymphoma | Peripheral T-cell Lymphoma | Lymphoblastic Leukemia, Acute, Childhood

United States, Canada, Australia
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Terminated

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Multiple Myeloma

United States
Assistance Publique Hopitaux De Marseille

Completed

A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours. (SFCE METRO 01)

Survival Without Progression

France
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

Multiple Myeloma in Relapse

France
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb

Completed

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Melanoma

United States
Jagannadha R Avasarala

Terminated

Diagnosis of ON With or Without MS or NMOSD

Multiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Neuromyelitis Optica Spectrum Disorder Relapse | Neuromyelitis Optica Spectrum Disorder Progression

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Centre Leon Berard

Completed

Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics) (SBRT)

Ependymoma | Brain Metastasis | Lung Tumors | Spinal Tumors

France
Rush University Medical Center
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Terminated

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
European Society for Blood and Marrow Transplantation
Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development...

Terminated

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Multiple Myeloma

France, Israel, Germany, Switzerland, Hungary, Czechia, United Kingdom, Austria, Belgium, Italy
AbbVie
Genentech, Inc.

Completed

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Relapsed/Refractory Multiple Myeloma

United States, Australia, France
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Dana-Farber Cancer Institute
Brigham and Women's Hospital; Genzyme, a Sanofi Company; Millennium Pharmaceuticals...

Completed

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
Grupo Español de Linfomas y Transplante Autólogo...

Unknown

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT (MAN2)

Mantle-cell Lymphoma

Spain
Janssen Research & Development, LLC

Completed

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Multiple Myeloma

France
Sellas Life Sciences Group

Unknown

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Multiple Myeloma | Minimal Residual Disease | High-Risk Cancer

United States
Centre Leon Berard

Terminated

BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) (BENEFIT)

Follicular Lymphoma

France
Instituto de Seguridad y Servicios Sociales de...

Unknown

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans (MM-POM-2018)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

Mexico
Fondazione EMN Italy Onlus

Completed

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Multiple Myeloma

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genzyme, a Sanofi Company

Terminated

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (POE07-01)

Acute Myeloid Leukemia | Myeloproliferative Disorders | Myelofibrosis | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Promyelocytic Leukemia | Chronic Myelogenous Leukemia

United States, Canada
Centre Leon Berard

Suspended

A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (CHONRAD)

Chondrosarcoma

France
SCRI Development Innovations, LLC
Novartis

Terminated

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
University of Arkansas

Withdrawn

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Adult Non-Hodgkin Lymphoma

United States
GlaxoSmithKline

Completed

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Lymphoma, Large-Cell, Diffuse

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Withdrawn

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Multiple Myeloma
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States

Search clinical trials for: Relapse or progression

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations